Find C-Met Inhibitors, ARQ 197 Inhibitor, Tivantinib Inhibitor on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)

SGX-523 1022150-57-7

Product Description

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

359.41 SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.


Biological Activity


SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor
(HGFR) tyrosine kinase Inhibitors. SGX-523 stabilizes MET in a unique
inactive conformation that is inaccessible to Other protein kinases,
suggesting an explanation for its selectivity. SGX523 potently inhibits
the purified MET catalytic domain but not the closely related receptor
tyrosine kinase RON. SGX523 indicates ATP-competitive inhibition with
higher apparent affinity for the less active, unphosphorylated form of
MET [MET-KD(0P), with a Ki of 2.7 nM] versus the more active
phospho-enzyme [MET-KD(3P), with a Ki of 23 nM], a phenomenon consistent
with preferential binding to an inactive enzyme conformation.


SGX523
inhibits MET-mediated signaling, cell proliferation and cell migration
at nanomolar concentrations but had no effect on signaling dependent on
other protein kinases, including the closely related RON, even at
micromolar concentrations.


SGX523 significantly retards the growth of preestablished GTL16 tumors
when administered orally at doses of ≥10 mg/kg twice daily. SGX523
potently inhibits U87MG tumor growth; at 30 mg/kg dosed twice daily,
SGX523 leads to clear regression of U87MG tumors.


SGX523, dosed twice
daily at 30 mg/kg, also retards the growth of H441 tumors with
concomitant reduction in tumor MET autophosphorylation levels. SGX523
inhibition of MET in vivo is associated with the dose-dependent
inhibition of growth of tumor xenografts derived from human
glioblastoma, lung and gastric cancers, confirming the dependence of
these tumors on MET catalytic activity.


Kinase assays


Initial rate constants are measured at 21 °C in the presence of 100 mM
HEPES (pH 7.5), 0.3 mg/mL poly(Glu-Tyr) peptide substrate, 10 mM MgCl2,
1 mg/mL bovine serum albumin, 5% DMSO, 20 nM MET-KD and various
concentrations of ATP and SGX523. Total reaction volumes (20 μL) are
quenched with 20 μL Kinase-Glo detection buffer. Luminescence is
detected in a plate-reading luminometer and the results are analyzed by
nonlinear regression.


Method


MDCK cells are seeded at 1 × 103 per well in a 24-well plate and incubated at 37 °C in 5% CO2 for 1 week in MEM and 10% fetal bovine serum. HGF (90 ng/mL) and
various concentrations of SGX523 are added and the cells are incubated
for another 18 hours (37 °C, 5% CO2 humidified incubator) and visualized. A549 cells are plated in 12-well plates (6 × 104 per well) and incubated to confluence to investigate cell migration. A
channel is introduced into the monolayers by scratching with a pipette
tip. Various dilutions of compound are added in starve medium in the
presence and absence of HGF (90 ng/mL).The wells are checked for cell
migration after twenty-fou

Contact us if you need more details on 1022150-57-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about SGX-523 1022150-57-7、1022150-57-7 SGX-523. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Protein Tyrosine Kinase > c-Met Inhibitor

Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters